Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daridorexant - Idorsia Pharmaceuticals

Next Previous
Drug Profile

Daridorexant - Idorsia Pharmaceuticals

Alternative Names: ACT 541468; Daridorexant hydrochloride - Idorsia Pharmaceuticals; DORA; Nemorexant - Idorsia Pharmaceuticals; QUVIVIQ

Latest Information Update: 19 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Department of defence; Idorsia Pharmaceuticals; Nxera Pharma; Shionogi; Simcere Pharmaceutical Group
  • Class Anxiolytics; Benzimidazoles; Chlorinated hydrocarbons; Ketones; Pyrrolidines; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Insomnia
  • Phase II Post-traumatic stress disorders
  • No development reported Sleep apnoea syndrome

Most Recent Events

  • 10 Mar 2026 Daridorexant licensed to Pharmalink in United Arab Emirates, Kuwait, Qatar, Oman, and Bahrain
  • 04 Mar 2026 Preregistration for Insomnia in South Korea (PO)
  • 05 Feb 2026 Idorsia Pharmaceuticals completes phase II clinical trials in Insomnia (In adolescents, In children) in US, Bulgaria, Germany, Spain, Belgium, Italy and Switzerland (PO) (NCT05423717)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top